Published in Cancer Weekly, August 17th, 2004
The company has been upgrading and expanding its production capabilities for its natural human alpha interferon drug. The company previously reported that it expects to report data later this year from studies evaluating Multiferon for the treatment of malignant melanoma.
Construction of the Ersboda facility was completed earlier this year and is currently undergoing validation required by the Swedish regulatory authorities.
Viragen is a biotechnology company specializing in the research,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.